Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02219659 · ClinicalTrials.gov registry record · NA
Pilot Study on Pairing Sedation Strategies and Weaning
A NA study, sponsored by MemorialCare Health System.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT02219659: Completed NA study, sponsored by MemorialCare Health System.
NCT02219659 is a NA study that has completed, run by MemorialCare Health System. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02219659, a NA study, has completed, sponsored by MemorialCare Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
A three-arm, randomized, pilot study, to assess the feasibility for the analgesia-first sedation (AFS) study arm/intervention (Fentanyl push first). The study will assess additional outcomes for all three (3) validated strategies for sedation and pain management.
Primary Outcome
Study feasibility for all 3 Arms/Groups (i.e., "Fentanyl Push First", "Sedation Protocol Without Interruption", and "Sedation Protocol with Interruption") being greater than or equal to 80% and protocol feasibility was based on protocol compliance (total percentage of study days participants were compliant with protocol).
Interventions
- DRUG Sedation Protocol with Daily Interruption
- DRUG Sedation Protocol Without Daily Interruption
- DRUG Fentanyl Push First
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-05-18 |
| Phase | NA |
What the finished NCT02219659 record still lists
NCT02219659 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Sedation Protocol with Daily Interruption is the first listed.
NCT02219659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02219659 about?
NCT02219659 is a clinical study titled "Pilot Study on Pairing Sedation Strategies and Weaning". A three-arm, randomized, pilot study, to assess the feasibility for the analgesia-first sedation (AFS) study arm/intervention (Fentanyl push first). The study will assess additional outcomes for all three (3) validated strategies for sedation and pain management.
What is the current status of trial NCT02219659?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2014-12. Estimated completion is 2018-05-18.
What interventions are being tested in trial NCT02219659?
The interventions under investigation include: Sedation Protocol with Daily Interruption (DRUG), Sedation Protocol Without Daily Interruption (DRUG), Fentanyl Push First (DRUG).
Who is sponsoring clinical trial NCT02219659?
This trial is sponsored by MemorialCare Health System, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02219659's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia